Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.66 |
| ▸ | ATM | Q13315 | 10/20 | 0.66 |
| ▸ | PRKDC | P78527 | 6/20 | 0.66 |
| ▸ | GSK3B | P49841 | 3/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14916345 | 0.93 | ATR (0.66) | ATRATMPRKDCGSK3B | |
| SCHEMBL10138726 | 0.85 | ATR (0.76) | ATRATMPRKDCGSK3B | |
| SCHEMBL14927218 | 0.81 | ATR (0.47) | ATRATMPRKDCGSK3B | |
| SCHEMBL14941384 | 0.80 | ATR (0.66) | ATRATMPRKDCGSK3B | |
| SCHEMBL30275264 | 0.79 | ATR (1.00) | ATRATMPRKDCGSK3B | |
| SCHEMBL2513058 | 0.78 | ATR (1.00) | ATRATMPRKDCGSK3B | |
| SCHEMBL10309250 | 0.78 | ATR (0.63) | ATRATMPRKDCGSK3B | |
| SCHEMBL14917422 | 0.77 | ATR (1.00) | ATRATMPRKDCGSK3B | |
| SCHEMBL3055539 | 0.76 | ATR (0.65) | ATRATMPRKDCGSK3B | |
| SCHEMBL10309268 | 0.76 | ATR (0.62) | ATRATMPRKDCGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841337-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130115312-A1 | Compounds Useful as Inhibitors of ATR Kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115312-A1 | Compounds Useful as Inhibitors of ATR Kinase | ATR, CHEK1, CHEK2 | ATR 1/4885ATM 31/4885PRKDC 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.